Alarmins (IL-33, sST2, HMGB1, and S100B) as potential biomarkers for schizophrenia

There is growing evidence that immune/inflammatory processes are related to the etiology of schizophrenia. Danger-/damage-associated molecular patterns (DAMPs), also called alarmins, are recognized as inflammatory mediators that play an important role in the development of many infection-induced or...

Full description

Saved in:
Bibliographic Details
Published inJournal of psychiatric research Vol. 138; pp. 380 - 387
Main Authors Kozłowska, Elżbieta, Brzezińska-Błaszczyk, Ewa, Agier, Justyna, Wysokiński, Adam, Żelechowska, Paulina
Format Journal Article
LanguageEnglish
Published England Elsevier Ltd 01.06.2021
Subjects
Online AccessGet full text

Cover

Loading…
Abstract There is growing evidence that immune/inflammatory processes are related to the etiology of schizophrenia. Danger-/damage-associated molecular patterns (DAMPs), also called alarmins, are recognized as inflammatory mediators that play an important role in the development of many infection-induced or sterile inflammatory diseases. The importance of DAMPs particles in various mental disorders is still not clear. Therefore, this study aimed to evaluate serum levels of the most promising alarmins (IL-33, sST2, HMGB1, and S100B), as potent schizophrenia biomarkers. Sixty-eight adult patients with chronic schizophrenia and twenty-nine healthy volunteers were included in this prospective study. Enzyme-linked immunosorbent assay (ELISA) was used to assess the serum concentration of IL-33, sST2, HMGB1, and S100B. We documented that the serum levels of IL-33 (p = 0.006), sST2 (p = 0.02), HMGB1 (p = 0.01), and S100B (p = 0.04) are significantly higher in patients with schizophrenia than in healthy subjects. In male, but not in female, patients with schizophrenia, we found a significant difference in the serum IL-33, sST2, and HMGB1 concentrations as compared to the healthy men. In both male and female patients with schizophrenia, there was no significant difference in the serum concentrations of S100B in comparison to control subjects. In patients with schizophrenia, no significant correlations were noticed neither between any studied alarmins and PANSS scores nor between CDSS scores. Given that all investigated alarmins participate in the course of the neuroinflammatory process, they might be considered as biomarkers of neuroinflammatory process underlying schizophrenia. Based on our observations, it seems that the most useful biological indicator of schizophrenia would be IL-33.
AbstractList There is growing evidence that immune/inflammatory processes are related to the etiology of schizophrenia. Danger-/damage-associated molecular patterns (DAMPs), also called alarmins, are recognized as inflammatory mediators that play an important role in the development of many infection-induced or sterile inflammatory diseases. The importance of DAMPs particles in various mental disorders is still not clear. Therefore, this study aimed to evaluate serum levels of the most promising alarmins (IL-33, sST2, HMGB1, and S100B), as potent schizophrenia biomarkers. Sixty-eight adult patients with chronic schizophrenia and twenty-nine healthy volunteers were included in this prospective study. Enzyme-linked immunosorbent assay (ELISA) was used to assess the serum concentration of IL-33, sST2, HMGB1, and S100B. We documented that the serum levels of IL-33 (p = 0.006), sST2 (p = 0.02), HMGB1 (p = 0.01), and S100B (p = 0.04) are significantly higher in patients with schizophrenia than in healthy subjects. In male, but not in female, patients with schizophrenia, we found a significant difference in the serum IL-33, sST2, and HMGB1 concentrations as compared to the healthy men. In both male and female patients with schizophrenia, there was no significant difference in the serum concentrations of S100B in comparison to control subjects. In patients with schizophrenia, no significant correlations were noticed neither between any studied alarmins and PANSS scores nor between CDSS scores. Given that all investigated alarmins participate in the course of the neuroinflammatory process, they might be considered as biomarkers of neuroinflammatory process underlying schizophrenia. Based on our observations, it seems that the most useful biological indicator of schizophrenia would be IL-33.
There is growing evidence that immune/inflammatory processes are related to the etiology of schizophrenia. Danger-/damage-associated molecular patterns (DAMPs), also called alarmins, are recognized as inflammatory mediators that play an important role in the development of many infection-induced or sterile inflammatory diseases. The importance of DAMPs particles in various mental disorders is still not clear. Therefore, this study aimed to evaluate serum levels of the most promising alarmins (IL-33, sST2, HMGB1, and S100B), as potent schizophrenia biomarkers. Sixty-eight adult patients with chronic schizophrenia and twenty-nine healthy volunteers were included in this prospective study. Enzyme-linked immunosorbent assay (ELISA) was used to assess the serum concentration of IL-33, sST2, HMGB1, and S100B. We documented that the serum levels of IL-33 (p = 0.006), sST2 (p = 0.02), HMGB1 (p = 0.01), and S100B (p = 0.04) are significantly higher in patients with schizophrenia than in healthy subjects. In male, but not in female, patients with schizophrenia, we found a significant difference in the serum IL-33, sST2, and HMGB1 concentrations as compared to the healthy men. In both male and female patients with schizophrenia, there was no significant difference in the serum concentrations of S100B in comparison to control subjects. In patients with schizophrenia, no significant correlations were noticed neither between any studied alarmins and PANSS scores nor between CDSS scores. Given that all investigated alarmins participate in the course of the neuroinflammatory process, they might be considered as biomarkers of neuroinflammatory process underlying schizophrenia. Based on our observations, it seems that the most useful biological indicator of schizophrenia would be IL-33.There is growing evidence that immune/inflammatory processes are related to the etiology of schizophrenia. Danger-/damage-associated molecular patterns (DAMPs), also called alarmins, are recognized as inflammatory mediators that play an important role in the development of many infection-induced or sterile inflammatory diseases. The importance of DAMPs particles in various mental disorders is still not clear. Therefore, this study aimed to evaluate serum levels of the most promising alarmins (IL-33, sST2, HMGB1, and S100B), as potent schizophrenia biomarkers. Sixty-eight adult patients with chronic schizophrenia and twenty-nine healthy volunteers were included in this prospective study. Enzyme-linked immunosorbent assay (ELISA) was used to assess the serum concentration of IL-33, sST2, HMGB1, and S100B. We documented that the serum levels of IL-33 (p = 0.006), sST2 (p = 0.02), HMGB1 (p = 0.01), and S100B (p = 0.04) are significantly higher in patients with schizophrenia than in healthy subjects. In male, but not in female, patients with schizophrenia, we found a significant difference in the serum IL-33, sST2, and HMGB1 concentrations as compared to the healthy men. In both male and female patients with schizophrenia, there was no significant difference in the serum concentrations of S100B in comparison to control subjects. In patients with schizophrenia, no significant correlations were noticed neither between any studied alarmins and PANSS scores nor between CDSS scores. Given that all investigated alarmins participate in the course of the neuroinflammatory process, they might be considered as biomarkers of neuroinflammatory process underlying schizophrenia. Based on our observations, it seems that the most useful biological indicator of schizophrenia would be IL-33.
Author Kozłowska, Elżbieta
Żelechowska, Paulina
Wysokiński, Adam
Brzezińska-Błaszczyk, Ewa
Agier, Justyna
Author_xml – sequence: 1
  givenname: Elżbieta
  surname: Kozłowska
  fullname: Kozłowska, Elżbieta
  email: elzbieta.kozlowska@umed.lodz.pl
  organization: Department of Experimental Immunology, Medical University of Lodz, Lodz, Poland
– sequence: 2
  givenname: Ewa
  surname: Brzezińska-Błaszczyk
  fullname: Brzezińska-Błaszczyk, Ewa
  organization: Department of Experimental Immunology, Medical University of Lodz, Lodz, Poland
– sequence: 3
  givenname: Justyna
  surname: Agier
  fullname: Agier, Justyna
  organization: Department of Experimental Immunology, Medical University of Lodz, Lodz, Poland
– sequence: 4
  givenname: Adam
  orcidid: 0000-0002-6159-6579
  surname: Wysokiński
  fullname: Wysokiński, Adam
  organization: Department of Old Age Psychiatry and Psychotic Disorders, Medical University of Lodz, Lodz, Poland
– sequence: 5
  givenname: Paulina
  surname: Żelechowska
  fullname: Żelechowska, Paulina
  organization: Department of Experimental Immunology, Medical University of Lodz, Lodz, Poland
BackLink https://www.ncbi.nlm.nih.gov/pubmed/33957300$$D View this record in MEDLINE/PubMed
BookMark eNqNkF1LIzEUQIO4rNXdvyB5dKEz3iTzkXmRteIXdFlY3eeQZu5g6jQZk6lQf72RKoJPfQpczj25nEOy77xDQiiDnAGrTpf5cogb82ADxpwDZzkUObBmj0yYrJuMibrZJxMAzjPRlNUBOYxxCQA1Z8V3ciDSsBYAE_LvvNdhZV2kJ7fzTIgpjXf3fEpv_lzP2JRq19I7BjD7RXWkgx_RjVb3dGH9SodHDJF2PtCYTnnxw0NAZ_UP8q3TfcSf7-8R-X91eX9xk83_Xt9enM8zU0g2Zl2pOZoSmgZ53RWgRVujNlK2rBasrljV8oWUmgkhSwOdrLisRAdNJ03VGhRH5GTrHYJ_WmMc1cpGg32vHfp1VLzkhah4Azyhx-_oerHCVg3BpvM36qNDAs62gAk-xoCdMnbUo_VuDNr2ioF6C6-W6jO8eguvoFApfBLIL4KPP3ZYnW1XMcV6thhUNBadwTahZlStt7tIfn-RmN46a3T_iJvdFK8eSbbS
CitedBy_id crossref_primary_10_2139_ssrn_4175654
crossref_primary_10_1016_j_neubiorev_2024_105949
crossref_primary_10_3390_ijms232113054
crossref_primary_10_1016_j_ejphar_2025_177469
crossref_primary_10_3390_medicina58060694
crossref_primary_10_1186_s43045_024_00395_9
crossref_primary_10_3390_brainsci13091334
crossref_primary_10_4081_itjm_2024_1830
crossref_primary_10_1007_s11126_024_10102_w
crossref_primary_10_1016_j_jneuroim_2024_578466
crossref_primary_10_1007_s00406_023_01677_9
crossref_primary_10_1038_s41398_023_02490_7
crossref_primary_10_3389_fncel_2023_1163764
crossref_primary_10_3389_fpsyt_2023_1241422
crossref_primary_10_3390_ijms231911245
crossref_primary_10_1080_20473869_2023_2301185
crossref_primary_10_3389_fnins_2023_1243168
crossref_primary_10_33393_jcb_2021_2327
crossref_primary_10_1016_j_psychres_2022_114762
crossref_primary_10_1017_neu_2022_37
crossref_primary_10_3390_ijms24119413
crossref_primary_10_3389_fpsyt_2022_1024299
crossref_primary_10_3390_ijms24043402
crossref_primary_10_30773_pi_2022_0173
crossref_primary_10_1016_j_jneuroim_2022_577951
crossref_primary_10_1016_j_ajp_2023_103788
crossref_primary_10_2298_SARH220417081L
Cites_doi 10.3389/fimmu.2019.02536
10.9758/cpn.2019.17.2.244
10.1016/j.neulet.2009.06.019
10.1074/jbc.R400025200
10.3389/fncel.2020.00274
10.1002/jemt.10303
10.1016/j.imbio.2015.02.005
10.1007/978-3-211-98811-4_46
10.1159/000446825
10.1172/JCI62423
10.1186/s12974-020-01806-4
10.5455/jmood.20150929074204
10.1186/1476-9255-8-22
10.1038/sj.npp.1300403
10.1016/j.bbi.2017.10.025
10.30773/pi.2018.12.19.1
10.1016/S0022-3956(01)00003-6
10.1016/j.jneuroim.2019.576993
10.1016/j.jpsychires.2010.04.023
10.1093/schbul/sbx121
10.1111/imr.12577
10.1038/cmi.2016.34
10.1016/j.schres.2005.04.013
10.1073/pnas.1604032113
10.4110/in.2018.18.e27
10.1007/s12035-012-8264-y
10.3389/fimmu.2018.02379
10.2174/156652413804486214
10.3389/fncel.2019.00127
10.1016/j.jad.2013.12.042
10.1186/1742-2094-7-6
10.1155/2020/8465083
10.1007/s10072-018-3611-z
10.1515/bmc-2016-0026
10.1007/s12028-007-0008-x
10.1001/jamapsychiatry.2019.3360
10.1111/jnc.14574
10.1189/jlb.0306164
10.3389/fimmu.2017.00475
10.1093/gerona/glq004
10.3109/08039488.2014.984755
10.3389/fpsyt.2018.00271
10.1016/j.cytogfr.2019.05.009
10.1111/j.1471-4159.2011.07612.x
10.1016/j.comppsych.2019.152118
10.1038/srep27584
10.1016/j.nbd.2016.02.018
10.1155/2010/656481
10.1007/s00701-016-3046-3
10.1016/j.schres.2013.10.011
10.1016/j.comppsych.2017.01.008
10.1038/onc.2016.104
10.3389/fpsyt.2019.00892
10.1111/jnc.14450
10.1016/j.psychres.2008.01.002
10.4049/jimmunol.1601342
ContentType Journal Article
Copyright 2021 The Author(s)
Copyright © 2021 The Author(s). Published by Elsevier Ltd.. All rights reserved.
Copyright_xml – notice: 2021 The Author(s)
– notice: Copyright © 2021 The Author(s). Published by Elsevier Ltd.. All rights reserved.
DBID 6I.
AAFTH
AAYXX
CITATION
NPM
7X8
DOI 10.1016/j.jpsychires.2021.04.019
DatabaseName ScienceDirect Open Access Titles
Elsevier:ScienceDirect:Open Access
CrossRef
PubMed
MEDLINE - Academic
DatabaseTitle CrossRef
PubMed
MEDLINE - Academic
DatabaseTitleList

PubMed
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1879-1379
EndPage 387
ExternalDocumentID 33957300
10_1016_j_jpsychires_2021_04_019
S0022395621002454
Genre Journal Article
GroupedDBID ---
--K
--M
.1-
.FO
.GJ
.~1
0R~
1B1
1P~
1RT
1~.
1~5
29L
4.4
457
4G.
53G
5GY
5RE
5VS
7-5
71M
8P~
9JM
9JO
AABNK
AADFP
AAEDT
AAEDW
AAGJA
AAGUQ
AAIKJ
AAKOC
AALRI
AAOAW
AAQFI
AAQXK
AATTM
AAXKI
AAXLA
AAXUO
AAYWO
ABBQC
ABCQJ
ABFNM
ABIVO
ABJNI
ABLJU
ABMAC
ABMZM
ABOYX
ABPPZ
ABWVN
ABXDB
ACDAQ
ACGFS
ACHQT
ACIEU
ACIUM
ACNCT
ACRLP
ACRPL
ACVFH
ACXNI
ADBBV
ADCNI
ADEZE
ADMUD
ADNMO
ADXHL
AEBSH
AEIPS
AEKER
AENEX
AEUPX
AEVXI
AFJKZ
AFPUW
AFRHN
AFTJW
AFXIZ
AGCQF
AGHFR
AGQPQ
AGUBO
AGWIK
AGYEJ
AHHHB
AIEXJ
AIGII
AIIUN
AIKHN
AITUG
AJRQY
AJUYK
AKBMS
AKRWK
AKYEP
ALMA_UNASSIGNED_HOLDINGS
AMRAJ
ANKPU
ANZVX
APXCP
ASPBG
AVWKF
AXJTR
AZFZN
BKOJK
BLXMC
BNPGV
CS3
DU5
EBS
EFJIC
EFKBS
EJD
EO8
EO9
EP2
EP3
F5P
FDB
FEDTE
FGOYB
FIRID
FNPLU
FYGXN
G-2
G-Q
GBLVA
HEG
HF~
HMK
HMO
HMQ
HMW
HVGLF
HZ~
IHE
J1W
K-O
KOM
L7B
M29
M2V
M39
M3V
M41
MO0
MOBAO
N9A
O-L
O9-
OAUVE
OH0
OKEIE
OU-
OZT
P-8
P-9
P2P
PC.
Q38
R2-
ROL
RPZ
SAE
SCC
SDF
SDG
SDP
SEL
SES
SEW
SNS
SPCBC
SPS
SSB
SSH
SSN
SSY
SSZ
T5K
WUQ
YQT
Z5R
ZGI
~G-
6I.
AACTN
AADPK
AAFTH
AAIAV
ABLVK
ABYKQ
AFCTW
AFKWA
AFYLN
AJBFU
AJOXV
AMFUW
EFLBG
LCYCR
RIG
ZA5
AAYXX
AGRNS
CITATION
NPM
7X8
ID FETCH-LOGICAL-c481t-f5a2ec5099e27f40a3d7eac88d17317616d2b88a13385c0f862863f09f8c6dce3
IEDL.DBID .~1
ISSN 0022-3956
1879-1379
IngestDate Fri Jul 11 16:32:35 EDT 2025
Mon Jul 21 05:33:58 EDT 2025
Tue Jul 01 01:04:00 EDT 2025
Thu Apr 24 22:57:53 EDT 2025
Fri Feb 23 02:46:13 EST 2024
Tue Aug 26 16:32:22 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Keywords Schizophrenia
Biomarkers
sST2
HMGB1
S100B
IL-33
Language English
License This is an open access article under the CC BY license.
Copyright © 2021 The Author(s). Published by Elsevier Ltd.. All rights reserved.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c481t-f5a2ec5099e27f40a3d7eac88d17317616d2b88a13385c0f862863f09f8c6dce3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ORCID 0000-0002-6159-6579
OpenAccessLink https://www.sciencedirect.com/science/article/pii/S0022395621002454
PMID 33957300
PQID 2524362902
PQPubID 23479
PageCount 8
ParticipantIDs proquest_miscellaneous_2524362902
pubmed_primary_33957300
crossref_citationtrail_10_1016_j_jpsychires_2021_04_019
crossref_primary_10_1016_j_jpsychires_2021_04_019
elsevier_sciencedirect_doi_10_1016_j_jpsychires_2021_04_019
elsevier_clinicalkey_doi_10_1016_j_jpsychires_2021_04_019
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2021-06-01
PublicationDateYYYYMMDD 2021-06-01
PublicationDate_xml – month: 06
  year: 2021
  text: 2021-06-01
  day: 01
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
PublicationTitle Journal of psychiatric research
PublicationTitleAlternate J Psychiatr Res
PublicationYear 2021
Publisher Elsevier Ltd
Publisher_xml – name: Elsevier Ltd
References Rothermundt, Peters, Prehn, Arolt (bib46) 2003; 60
Kleindienst, Meissner, Eyupoglu, Parsch, Schmidt, Buchfelder (bib31) 2010; 106
Borsky, Fiala, Andrys, Beranek, Hamakova, Malkova, Svadlakova, Krejsek, Palicka, Borska, Rehacek (bib13) 2020; 2020
Franklin, Xu, Duman (bib24) 2018; 72
Santoro, Maetzler, Stathakos, Martin, Hobert, Rattay, Gasser, Forrester, Berg, Tracey, Riedel, Teismann (bib48) 2016; 91
Saresella, Marventano, Piancone, La Rosa, Galimberti, Fenoglio, Scarpini, Clerici (bib49) 2020; 17
Qi, Xiu, Chen, Wang, Kosten, Kosten, Zhang (bib42) 2009; 462
Wysokiński, Margulska, Strzelecki, Kłoszewska (bib58) 2015; 69
Chan, Roth, Oppenheim, Tracey, Vogl, Feldmann, Horwood, Nanchahal (bib15) 2012; 122
Hong, Zhao, Li, Peng, Wang, Li, Xiang, Su, Huang, Zhang, Zhao, Zhou, Mao, Lin, Fang, Zhang, Xie (bib28) 2016; 6
Trovão, Prata, VonDoellinger, Santos, Barbosam, Coelho (bib55) 2019; 16
Demir, Bulut, Kaya, Sevim, Demirpence, Ibiloglu, Gunes, Atli, Yasin (bib20) 2015; 5
Griesenauer, Paczesny (bib26) 2017; 8
Bertheloot, Latz (bib8) 2017; 14
Alsahebfosoul, Rahimmanesh, Shajarian, Etemadifar, Sedaghat, Hejazi, Naderi (bib2) 2017; 8
de Campos-Carli, Miranda, Dias, de Oliveira, Cruz, Vieira, Rocha, Barbosa, Salgado, Teixeira (bib19) 2017; 74
Comer, Carrier, Tremblay, Cruz-Martín (bib18) 2020; 14
Denning, Aziz, Gurien, Wang (bib21) 2019; 10
Al-Dujaili, Mousa, Al-Hakeim, Maes (bib1) 2020
Schmitt, Bertsch, Henning, Tost, Klimke, Henn, Falkai (bib50) 2005; 80
Barbosa, Morato, de Miranda, Bauer, Soares, Teixeira (bib7) 2014; 157
Zhu, Hu, Zhou, Qiao, Chang, Tong (bib62) 2019; 94
Zhu, Li, Hie, Yuan, Lü, Song (bib63) 2015; 95
Lu, Zhang, Barnie, Su (bib33) 2019; 47
Miller (bib38) 2011; 8
North, Bruggemann, Cropley, Swaminathan, Sundram, Lenroot, Pereira, Zalesky, Bousman, Pantelis, Weickert, Shannon Weickert (bib41) 2021; 24
Ye, Zeng, Jin, Zhang, Xiong, Gu (bib60) 2019; 13
Angelopoulou, Piperi, Papavassiliou (bib4) 2018; 146
Sorci, Bianchi, Riuzzi, Tubaro, Arcuri, Giambanco, Donato (bib52) 2010
Janoutová, Janácková, Serý, Zeman, Ambroz, Kovalová, Varechová, Hosák, Jirík, Janout (bib29) 2016; 37
Tourjman, Kouassi, Koué, Rocchetti, Fortin-Fournier, Fusar-Poli, Potvin (bib54) 2013; 151
Vocca, Di Sano, Uasuf, Sala, Riccobono, Gangemi, Albano, Bonanno, Gagliardo, Profita (bib56) 2015; 220
Fu, Hung, Yuen, Zhou, Mak, Chan, Cheung, Zhang, Fu, Liew, Ip (bib25) 2016; 113
Chen, He, Tu, Duan (bib17) 2020; 35
Lara, Gama, Belmonte-de-Abreu, Portela, Gonçalves, Fonseca, Hauck, Souza (bib32) 2001; 35
Momtazmanesh, Zare-Shahabadi, Rezaei (bib39) 2019; 10
McCutcheon, Reis Marques, Howes (bib35) 2020; 77
Rothermundt, Ponath, Glaserm, Hetzel, Arolt (bib47) 2004; 29
Black, Kushner, Samols (bib10) 2004; 279
Schroeter, Abdul-Khaliq, Krebs, Diefenbacher, Blasigm (bib51) 2009; 167
Hernandez, Huebener, Schwabe (bib27) 2016; 35
Donato, Cannon, Sorci (bib22) 2013; 13
Arora, Sagar, Mehta, Pallavi, Sharma, Mukhopadhyay (bib5) 2019; 61
Michetti, Corvino, Geloso, Lattanzi, Bernardini, Serpero, Gazzolo (bib36) 2012; 120
Marie-Claire, Courtin, Curis, Bouaziz-Amar, Laplanche, Jacob, Etain, Blanchard, Bellivier (bib34) 2019; 334
Chaves, Camozzato, Ferreira, Piazenski, Kochhann, Dall'Igna, Mazzini, Souza, Portela (bib16) 2010; 7
Baran, Bulut, Kaya, Demirpençe, Sevim, Akıl, Varol (bib6) 2019; 40
Rider, Voronov, Dinarello, Apte, Cohen (bib44) 2017; 198
Michetti, D'Ambrosi, Toesca, Puglisi, Serrano, Marchese, Corvino, Geloso (bib37) 2019; 148
Yang, Han, Oppenheim (bib59) 2017; 280
Thelin, Nelson, Bellander (bib53) 2017; 159
Bianchi (bib9) 2007; 81
Amarante-Mendes, Adjemian, Branco, Zanetti, Weinlich, Bortoluci (bib3) 2018; 9
Bruscia, Bonfield (bib14) 2016; 8
Borovcanin, Janicijevic, Jovanovic, Gajovic, Arsenijevic, Lukic (bib12) 2018; 9
Zhang, Xiu, Song, Chen, Wu, Haile, Kosten, Kosten (bib61) 2010; 44
Bloomfield, McKinney, Smith, Brisman (bib64) 2007; 6
Roh, Sohn (bib45) 2018; 18
Murray, Bhavsar, Tripoli, Howes (bib40) 2017; 43
Fang, Schachner, Shen (bib23) 2012; 45
Bolu, Aydın, Akgün, Coşkun, Garip, Öznur, Çelik, Uzun (bib11) 2019; 31
Willems, Trompet, Blauw, Westendorp, de Craen (bib57) 2010; 65
Karabulut, Taşdemir, Akcan, Küçükali, Tüzün, Çakır (bib30) 2019; 30
Trovão (10.1016/j.jpsychires.2021.04.019_bib55) 2019; 16
Michetti (10.1016/j.jpsychires.2021.04.019_bib37) 2019; 148
Saresella (10.1016/j.jpsychires.2021.04.019_bib49) 2020; 17
Sorci (10.1016/j.jpsychires.2021.04.019_bib52) 2010
Black (10.1016/j.jpsychires.2021.04.019_bib10) 2004; 279
Chaves (10.1016/j.jpsychires.2021.04.019_bib16) 2010; 7
Demir (10.1016/j.jpsychires.2021.04.019_bib20) 2015; 5
Griesenauer (10.1016/j.jpsychires.2021.04.019_bib26) 2017; 8
Schmitt (10.1016/j.jpsychires.2021.04.019_bib50) 2005; 80
Wysokiński (10.1016/j.jpsychires.2021.04.019_bib58) 2015; 69
Lara (10.1016/j.jpsychires.2021.04.019_bib32) 2001; 35
Zhang (10.1016/j.jpsychires.2021.04.019_bib61) 2010; 44
Barbosa (10.1016/j.jpsychires.2021.04.019_bib7) 2014; 157
Hernandez (10.1016/j.jpsychires.2021.04.019_bib27) 2016; 35
Vocca (10.1016/j.jpsychires.2021.04.019_bib56) 2015; 220
Arora (10.1016/j.jpsychires.2021.04.019_bib5) 2019; 61
Comer (10.1016/j.jpsychires.2021.04.019_bib18) 2020; 14
Bianchi (10.1016/j.jpsychires.2021.04.019_bib9) 2007; 81
Santoro (10.1016/j.jpsychires.2021.04.019_bib48) 2016; 91
Kleindienst (10.1016/j.jpsychires.2021.04.019_bib31) 2010; 106
Alsahebfosoul (10.1016/j.jpsychires.2021.04.019_bib2) 2017; 8
Michetti (10.1016/j.jpsychires.2021.04.019_bib36) 2012; 120
Ye (10.1016/j.jpsychires.2021.04.019_bib60) 2019; 13
Lu (10.1016/j.jpsychires.2021.04.019_bib33) 2019; 47
Zhu (10.1016/j.jpsychires.2021.04.019_bib63) 2015; 95
Momtazmanesh (10.1016/j.jpsychires.2021.04.019_bib39) 2019; 10
Qi (10.1016/j.jpsychires.2021.04.019_bib42) 2009; 462
Marie-Claire (10.1016/j.jpsychires.2021.04.019_bib34) 2019; 334
Hong (10.1016/j.jpsychires.2021.04.019_bib28) 2016; 6
Murray (10.1016/j.jpsychires.2021.04.019_bib40) 2017; 43
Chan (10.1016/j.jpsychires.2021.04.019_bib15) 2012; 122
Rothermundt (10.1016/j.jpsychires.2021.04.019_bib47) 2004; 29
Amarante-Mendes (10.1016/j.jpsychires.2021.04.019_bib3) 2018; 9
Chen (10.1016/j.jpsychires.2021.04.019_bib17) 2020; 35
Denning (10.1016/j.jpsychires.2021.04.019_bib21) 2019; 10
Schroeter (10.1016/j.jpsychires.2021.04.019_bib51) 2009; 167
Bloomfield (10.1016/j.jpsychires.2021.04.019_bib64) 2007; 6
Fang (10.1016/j.jpsychires.2021.04.019_bib23) 2012; 45
Borovcanin (10.1016/j.jpsychires.2021.04.019_bib12) 2018; 9
Zhu (10.1016/j.jpsychires.2021.04.019_bib62) 2019; 94
Janoutová (10.1016/j.jpsychires.2021.04.019_bib29) 2016; 37
de Campos-Carli (10.1016/j.jpsychires.2021.04.019_bib19) 2017; 74
Fu (10.1016/j.jpsychires.2021.04.019_bib25) 2016; 113
Bruscia (10.1016/j.jpsychires.2021.04.019_bib14) 2016; 8
Donato (10.1016/j.jpsychires.2021.04.019_bib22) 2013; 13
Baran (10.1016/j.jpsychires.2021.04.019_bib6) 2019; 40
Karabulut (10.1016/j.jpsychires.2021.04.019_bib30) 2019; 30
Willems (10.1016/j.jpsychires.2021.04.019_bib57) 2010; 65
North (10.1016/j.jpsychires.2021.04.019_bib41) 2021; 24
Rider (10.1016/j.jpsychires.2021.04.019_bib44) 2017; 198
Franklin (10.1016/j.jpsychires.2021.04.019_bib24) 2018; 72
McCutcheon (10.1016/j.jpsychires.2021.04.019_bib35) 2020; 77
Miller (10.1016/j.jpsychires.2021.04.019_bib38) 2011; 8
Tourjman (10.1016/j.jpsychires.2021.04.019_bib54) 2013; 151
Thelin (10.1016/j.jpsychires.2021.04.019_bib53) 2017; 159
Bertheloot (10.1016/j.jpsychires.2021.04.019_bib8) 2017; 14
Roh (10.1016/j.jpsychires.2021.04.019_bib45) 2018; 18
Yang (10.1016/j.jpsychires.2021.04.019_bib59) 2017; 280
Al-Dujaili (10.1016/j.jpsychires.2021.04.019_bib1) 2020
Bolu (10.1016/j.jpsychires.2021.04.019_bib11) 2019; 31
Angelopoulou (10.1016/j.jpsychires.2021.04.019_bib4) 2018; 146
Rothermundt (10.1016/j.jpsychires.2021.04.019_bib46) 2003; 60
Borsky (10.1016/j.jpsychires.2021.04.019_bib13) 2020; 2020
References_xml – volume: 17
  start-page: 174
  year: 2020
  ident: bib49
  article-title: IL-33 and its decoy sST2 in patients with Alzheimer's disease and mild cognitive impairment
  publication-title: J. Neuroinflammation
– volume: 9
  start-page: 271
  year: 2018
  ident: bib12
  article-title: IL-33/ST2 pathway and galectin-3 as a new analytes in pathogenesis and cardiometabolic risk evaluation in psychosis
  publication-title: Front. Psychiatr.
– volume: 37
  start-page: 1
  year: 2016
  end-page: 8
  ident: bib29
  article-title: Epidemiology and risk factors of schizophrenia
  publication-title: Neuroendocrinol. Lett.
– volume: 6
  start-page: 121
  year: 2007
  end-page: 138
  ident: bib64
  article-title: Reliability of S100B in predicting severity of central nervous system injury
  publication-title: Neurocrit. Care
– volume: 148
  start-page: 168
  year: 2019
  end-page: 187
  ident: bib37
  article-title: The S100B story: from biomarker to active factor in neural injury
  publication-title: J. Neurochem.
– volume: 334
  start-page: 576993
  year: 2019
  ident: bib34
  article-title: Increased plasma levels of high mobility group box 1 protein in patients with bipolar disorder: a pilot study
  publication-title: J. Neuroimmunol.
– volume: 61
  start-page: 70
  year: 2019
  end-page: 76
  ident: bib5
  article-title: Serum S100B levels in patients with depression
  publication-title: Indian J. Psychiatr.
– volume: 31
  start-page: 244
  year: 2019
  end-page: 249
  ident: bib11
  article-title: Serum levels of high sensitivity C-reactive protein in drug-naïve first-episode psychosis and acute exacerbation of schizophrenia
  publication-title: Clin Psychopharmacol Neurosci
– volume: 157
  start-page: 41
  year: 2014
  end-page: 44
  ident: bib7
  article-title: A preliminary report of increased plasma levels of IL-33 in bipolar disorder: further evidence of pro-inflammatory status
  publication-title: J. Affect. Disord.
– volume: 94
  start-page: 152118
  year: 2019
  ident: bib62
  article-title: Serum high-sensitivity C-reactive protein levels are positively associated with cognitive impairments in patients with first-episode schizophrenia
  publication-title: Compr. Psychiatr.
– volume: 2020
  start-page: 8465083
  year: 2020
  ident: bib13
  article-title: Alarmins HMGB1, IL-33, S100A7, and S100A12 in psoriasis vulgaris
  publication-title: Mediat. Inflamm.
– volume: 91
  start-page: 59
  year: 2016
  end-page: 68
  ident: bib48
  article-title: In-vivo evidence that high mobility group box 1 exerts deleterious effects in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model and Parkinson's disease which can be attenuated by glycyrrhizin
  publication-title: Neurobiol. Dis.
– year: 2010
  ident: bib52
  article-title: S100B protein, A damage-associated molecular pattern protein in the brain and heart, and beyond
  publication-title: Cardiovasc. Psychiatry. Neurol.
– volume: 40
  start-page: 167
  year: 2019
  end-page: 173
  ident: bib6
  article-title: High-sensitivity C-reactive protein and high mobility group box-1 levels in Parkinson's disease
  publication-title: Neurol. Sci.
– volume: 10
  start-page: 892
  year: 2019
  ident: bib39
  article-title: Cytokine alterations in schizophrenia: an updated review
  publication-title: Front. Psychiatr.
– volume: 122
  start-page: 2711
  year: 2012
  end-page: 2719
  ident: bib15
  article-title: Alarmins: awaiting a clinical response
  publication-title: J. Clin. Invest.
– volume: 462
  start-page: 113
  year: 2009
  end-page: 117
  ident: bib42
  article-title: Increased serum S100B levels in chronic schizophrenic patients on long-term clozapine or typical antipsychotics
  publication-title: Neurosci. Lett.
– volume: 81
  start-page: 1
  year: 2007
  end-page: 5
  ident: bib9
  article-title: DAMPs, PAMPs and alarmins: all we need to know about danger
  publication-title: J. Leukoc. Biol.
– volume: 220
  start-page: 954
  year: 2015
  end-page: 963
  ident: bib56
  article-title: IL-33/ST2 axis controls Th2/IL-31 and Th17 immune response in allergic airway diseases
  publication-title: Immunobiology
– volume: 47
  start-page: 74
  year: 2019
  end-page: 82
  ident: bib33
  article-title: Dual faced HMGB1 plays multiple roles in cardiomyocyte senescence and cardiac inflammatory injury
  publication-title: Cytokine Growth Factor Rev.
– volume: 8
  start-page: 550
  year: 2016
  end-page: 563
  ident: bib14
  article-title: Cystic fibrosis lung immunity: the role of the macrophage
  publication-title: J. Innate. Immun.
– volume: 60
  start-page: 614
  year: 2003
  end-page: 632
  ident: bib46
  article-title: S100B in brain damage and neurodegeneration
  publication-title: Microsc. Res. Tech.
– volume: 18
  start-page: e27
  year: 2018
  ident: bib45
  article-title: Damage-associated molecular patterns in inflammatory diseases
  publication-title: Immune. Netw.
– volume: 95
  start-page: 3818
  year: 2015
  end-page: 3822
  ident: bib63
  article-title: [Analysis of the changes of serum high mobility group protein B1 and cytokines in first-episode schizophrenia patients]
  publication-title: Zhonghua Yixue Zazhi
– volume: 9
  start-page: 2379
  year: 2018
  ident: bib3
  article-title: Pattern recognition receptors and the host cell death molecular machinery
  publication-title: Front. Immunol.
– volume: 106
  start-page: 247
  year: 2010
  end-page: 250
  ident: bib31
  article-title: Dynamics of S100B release into serum and cerebrospinal fluid following acute brain injury
  publication-title: Acta Neurochir. Suppl.
– volume: 35
  start-page: 5931
  year: 2016
  end-page: 5941
  ident: bib27
  article-title: Damage-associated molecular patterns in cancer: a double-edged sword
  publication-title: Oncogene
– volume: 35
  start-page: 137
  year: 2020
  end-page: 146
  ident: bib17
  article-title: Dual immune functions of IL-33 in inflammatory bowel disease
  publication-title: Histol. Histopathol.
– volume: 13
  start-page: 24
  year: 2013
  end-page: 57
  ident: bib22
  article-title: Functions of S100 proteins
  publication-title: Curr. Mol. Med.
– volume: 279
  start-page: 48487
  year: 2004
  end-page: 48490
  ident: bib10
  article-title: C-reactive protein
  publication-title: J. Biol. Chem.
– volume: 77
  start-page: 201
  year: 2020
  end-page: 210
  ident: bib35
  article-title: Schizophrenia-an overview
  publication-title: JAMA. Psychiatry.
– volume: 10
  start-page: 2536
  year: 2019
  ident: bib21
  article-title: DAMPs and NETs in sepsis
  publication-title: Front. Immunol.
– volume: 24
  year: 2021
  ident: bib41
  article-title: Increased peripheral inflammation in schizophrenia is associated with worse cognitive performance and related cortical thickness reductions
  publication-title: Eur. Arch. Psychiatr. Clin. Neurosci.
– volume: 7
  start-page: 6
  year: 2010
  ident: bib16
  article-title: Serum levels of S100B and NSE proteins in Alzheimer's disease patients
  publication-title: J. Neuroinflammation
– volume: 44
  start-page: 1236
  year: 2010
  end-page: 1240
  ident: bib61
  article-title: Increased serum S100B in never-medicated and medicated schizophrenic patients
  publication-title: J. Psychiatr. Res.
– volume: 8
  start-page: 55
  year: 2017
  end-page: 60
  ident: bib2
  article-title: Interleukin-33 plasma levels in patients with relapsing-remitting multiple sclerosis
  publication-title: Biomol. Concepts
– volume: 69
  start-page: 346
  year: 2015
  end-page: 353
  ident: bib58
  article-title: Levels of C-reactive protein (CRP) in patients with schizophrenia, unipolar depression and bipolar disorder
  publication-title: Nord. J. Psychiatr.
– volume: 120
  start-page: 644
  year: 2012
  end-page: 659
  ident: bib36
  article-title: The S100B protein in biological fluids: more than a lifelong biomarker of brain distress
  publication-title: J. Neurochem.
– volume: 14
  start-page: 43
  year: 2017
  end-page: 64
  ident: bib8
  article-title: HMGB1, IL-1α, IL-33 and S100 proteins: dual-function alarmins
  publication-title: Cell. Mol. Immunol.
– volume: 74
  start-page: 96
  year: 2017
  end-page: 101
  ident: bib19
  article-title: Serum levels of interleukin-33 and its soluble form receptor (sST2) are associated with cognitive performance in patients with schizophrenia
  publication-title: Compr. Psychiatr.
– volume: 8
  start-page: 22
  year: 2011
  ident: bib38
  article-title: Role of IL-33 in inflammation and disease
  publication-title: J. Inflamm.
– volume: 29
  start-page: 1004
  year: 2004
  end-page: 1011
  ident: bib47
  article-title: S100B serum levels and long-term improvement of negative symptoms in patients with schizophrenia
  publication-title: Neuropsychopharmacology
– volume: 16
  start-page: 177
  year: 2019
  end-page: 184
  ident: bib55
  article-title: Peripheral biomarkers for first-episode psychosis-opportunities from the neuroinflammatory hypothesis of schizophrenia
  publication-title: Psychiatry. Investig.
– volume: 198
  start-page: 1395
  year: 2017
  end-page: 1402
  ident: bib44
  article-title: Alarmins: feel the stress
  publication-title: J. Immunol.
– volume: 65
  start-page: 764
  year: 2010
  end-page: 768
  ident: bib57
  article-title: White blood cell count and C-reactive protein are independent predictors of mortality in the oldest old
  publication-title: J. Gerontol. A Biol. Sci. Med Sci.
– volume: 146
  start-page: 211
  year: 2018
  end-page: 218
  ident: bib4
  article-title: High-mobility group box 1 in Parkinson's disease: from pathogenesis to therapeutic approaches
  publication-title: J. Neurochem.
– volume: 8
  start-page: 475
  year: 2017
  ident: bib26
  article-title: The ST2/IL-33 Axis in immune cells during inflammatory diseases
  publication-title: Front. Immunol.
– volume: 151
  start-page: 43
  year: 2013
  end-page: 47
  ident: bib54
  article-title: Antipsychotics' effects on blood levels of cytokines in schizophrenia: a meta-analysis
  publication-title: Schizophr. Res.
– volume: 14
  start-page: 274
  year: 2020
  ident: bib18
  article-title: The inflamed brain in schizophrenia: the convergence of genetic and environmental risk factors that lead to uncontrolled neuroinflammation
  publication-title: Front. Cell. Neurosci.
– volume: 113
  start-page: E2705
  year: 2016
  end-page: E2713
  ident: bib25
  article-title: IL-33 ameliorates Alzheimer's disease-like pathology and cognitive decline
  publication-title: Proc. Natl. Acad. Sci. U.S.A.
– volume: 72
  start-page: 2
  year: 2018
  end-page: 13
  ident: bib24
  article-title: Depression and sterile inflammation: essential role of danger associated molecular patterns
  publication-title: Brain Behav. Immun.
– volume: 13
  start-page: 127
  year: 2019
  ident: bib60
  article-title: The role of high mobility group box 1 in ischemic stroke
  publication-title: Front. Cell. Neurosci.
– volume: 159
  start-page: 209
  year: 2017
  end-page: 225
  ident: bib53
  article-title: A review of the clinical utility of serum S100B protein levels in the assessment of traumatic brain injury
  publication-title: Acta Neurochir.
– volume: 30
  start-page: 75
  year: 2019
  end-page: 81
  ident: bib30
  article-title: [Inflammation and neurodegeneration in patients with early-stageand chronic bipolar disorder]
  publication-title: Türk PsikiyatriDerg.
– volume: 45
  start-page: 499
  year: 2012
  end-page: 506
  ident: bib23
  article-title: HMGB1 in development and diseases of the central nervous system
  publication-title: Mol. Neurobiol.
– volume: 280
  start-page: 41
  year: 2017
  end-page: 56
  ident: bib59
  article-title: Alarmins and immunity
  publication-title: Immunol. Rev.
– volume: 35
  start-page: 11
  year: 2001
  end-page: 14
  ident: bib32
  article-title: Increased serum S100B protein in schizophrenia: a study in medication-free patients
  publication-title: J. Psychiatr. Res.
– volume: 43
  start-page: 1190
  year: 2017
  end-page: 1196
  ident: bib40
  article-title: 30 Years on: how the neurodevelopmental hypothesis of schizophrenia morphed into the developmental risk factor model of psychosis
  publication-title: Schizophr. Bull.
– volume: 6
  start-page: 27584
  year: 2016
  ident: bib28
  article-title: Higher plasma S100B concentrations in schizophrenia patients, and dependently associated with inflammatory markers
  publication-title: Sci. Rep.
– volume: 5
  start-page: 145
  year: 2015
  ident: bib20
  article-title: Increased high mobility group Box1 (HMGB1) level in major depressive disorder
  publication-title: J. Mood Disord.
– year: 2020
  ident: bib1
  article-title: High mobility group protein 1 and dickkopf-related protein 1 in schizophrenia and treatment-resistant schizophrenia: associations with interleukin-6, symptom domains, and neurocognitive impairments
  publication-title: Schizophr. Bull.
– volume: 167
  start-page: 66
  year: 2009
  end-page: 72
  ident: bib51
  article-title: Neuron-specific enolase is unaltered whereas S100B is elevated in serum of patients with schizophrenia--original research and meta-analysis
  publication-title: Psychiatr. Res.
– volume: 80
  start-page: 305
  year: 2005
  end-page: 313
  ident: bib50
  article-title: Increased serum S100B in elderly, chronic schizophrenic patients: negative correlation with deficit symptoms
  publication-title: Schizophr. Res.
– volume: 10
  start-page: 2536
  year: 2019
  ident: 10.1016/j.jpsychires.2021.04.019_bib21
  article-title: DAMPs and NETs in sepsis
  publication-title: Front. Immunol.
  doi: 10.3389/fimmu.2019.02536
– volume: 31
  start-page: 244
  issue: 17
  year: 2019
  ident: 10.1016/j.jpsychires.2021.04.019_bib11
  article-title: Serum levels of high sensitivity C-reactive protein in drug-naïve first-episode psychosis and acute exacerbation of schizophrenia
  publication-title: Clin Psychopharmacol Neurosci
  doi: 10.9758/cpn.2019.17.2.244
– volume: 462
  start-page: 113
  issue: 2
  year: 2009
  ident: 10.1016/j.jpsychires.2021.04.019_bib42
  article-title: Increased serum S100B levels in chronic schizophrenic patients on long-term clozapine or typical antipsychotics
  publication-title: Neurosci. Lett.
  doi: 10.1016/j.neulet.2009.06.019
– year: 2020
  ident: 10.1016/j.jpsychires.2021.04.019_bib1
  article-title: High mobility group protein 1 and dickkopf-related protein 1 in schizophrenia and treatment-resistant schizophrenia: associations with interleukin-6, symptom domains, and neurocognitive impairments
  publication-title: Schizophr. Bull.
– volume: 279
  start-page: 48487
  year: 2004
  ident: 10.1016/j.jpsychires.2021.04.019_bib10
  article-title: C-reactive protein
  publication-title: J. Biol. Chem.
  doi: 10.1074/jbc.R400025200
– volume: 14
  start-page: 274
  year: 2020
  ident: 10.1016/j.jpsychires.2021.04.019_bib18
  article-title: The inflamed brain in schizophrenia: the convergence of genetic and environmental risk factors that lead to uncontrolled neuroinflammation
  publication-title: Front. Cell. Neurosci.
  doi: 10.3389/fncel.2020.00274
– volume: 60
  start-page: 614
  issue: 6
  year: 2003
  ident: 10.1016/j.jpsychires.2021.04.019_bib46
  article-title: S100B in brain damage and neurodegeneration
  publication-title: Microsc. Res. Tech.
  doi: 10.1002/jemt.10303
– volume: 24
  year: 2021
  ident: 10.1016/j.jpsychires.2021.04.019_bib41
  article-title: Increased peripheral inflammation in schizophrenia is associated with worse cognitive performance and related cortical thickness reductions
  publication-title: Eur. Arch. Psychiatr. Clin. Neurosci.
– volume: 220
  start-page: 954
  issue: 8
  year: 2015
  ident: 10.1016/j.jpsychires.2021.04.019_bib56
  article-title: IL-33/ST2 axis controls Th2/IL-31 and Th17 immune response in allergic airway diseases
  publication-title: Immunobiology
  doi: 10.1016/j.imbio.2015.02.005
– volume: 61
  start-page: 70
  issue: 1
  year: 2019
  ident: 10.1016/j.jpsychires.2021.04.019_bib5
  article-title: Serum S100B levels in patients with depression
  publication-title: Indian J. Psychiatr.
– volume: 106
  start-page: 247
  year: 2010
  ident: 10.1016/j.jpsychires.2021.04.019_bib31
  article-title: Dynamics of S100B release into serum and cerebrospinal fluid following acute brain injury
  publication-title: Acta Neurochir. Suppl.
  doi: 10.1007/978-3-211-98811-4_46
– volume: 8
  start-page: 550
  issue: 6
  year: 2016
  ident: 10.1016/j.jpsychires.2021.04.019_bib14
  article-title: Cystic fibrosis lung immunity: the role of the macrophage
  publication-title: J. Innate. Immun.
  doi: 10.1159/000446825
– volume: 122
  start-page: 2711
  issue: 8
  year: 2012
  ident: 10.1016/j.jpsychires.2021.04.019_bib15
  article-title: Alarmins: awaiting a clinical response
  publication-title: J. Clin. Invest.
  doi: 10.1172/JCI62423
– volume: 17
  start-page: 174
  issue: 1
  year: 2020
  ident: 10.1016/j.jpsychires.2021.04.019_bib49
  article-title: IL-33 and its decoy sST2 in patients with Alzheimer's disease and mild cognitive impairment
  publication-title: J. Neuroinflammation
  doi: 10.1186/s12974-020-01806-4
– volume: 5
  start-page: 145
  issue: 4
  year: 2015
  ident: 10.1016/j.jpsychires.2021.04.019_bib20
  article-title: Increased high mobility group Box1 (HMGB1) level in major depressive disorder
  publication-title: J. Mood Disord.
  doi: 10.5455/jmood.20150929074204
– volume: 8
  start-page: 22
  issue: 1
  year: 2011
  ident: 10.1016/j.jpsychires.2021.04.019_bib38
  article-title: Role of IL-33 in inflammation and disease
  publication-title: J. Inflamm.
  doi: 10.1186/1476-9255-8-22
– volume: 29
  start-page: 1004
  issue: 5
  year: 2004
  ident: 10.1016/j.jpsychires.2021.04.019_bib47
  article-title: S100B serum levels and long-term improvement of negative symptoms in patients with schizophrenia
  publication-title: Neuropsychopharmacology
  doi: 10.1038/sj.npp.1300403
– volume: 72
  start-page: 2
  year: 2018
  ident: 10.1016/j.jpsychires.2021.04.019_bib24
  article-title: Depression and sterile inflammation: essential role of danger associated molecular patterns
  publication-title: Brain Behav. Immun.
  doi: 10.1016/j.bbi.2017.10.025
– volume: 35
  start-page: 137
  issue: 2
  year: 2020
  ident: 10.1016/j.jpsychires.2021.04.019_bib17
  article-title: Dual immune functions of IL-33 in inflammatory bowel disease
  publication-title: Histol. Histopathol.
– volume: 16
  start-page: 177
  issue: 3
  year: 2019
  ident: 10.1016/j.jpsychires.2021.04.019_bib55
  article-title: Peripheral biomarkers for first-episode psychosis-opportunities from the neuroinflammatory hypothesis of schizophrenia
  publication-title: Psychiatry. Investig.
  doi: 10.30773/pi.2018.12.19.1
– volume: 35
  start-page: 11
  issue: 1
  year: 2001
  ident: 10.1016/j.jpsychires.2021.04.019_bib32
  article-title: Increased serum S100B protein in schizophrenia: a study in medication-free patients
  publication-title: J. Psychiatr. Res.
  doi: 10.1016/S0022-3956(01)00003-6
– volume: 334
  start-page: 576993
  year: 2019
  ident: 10.1016/j.jpsychires.2021.04.019_bib34
  article-title: Increased plasma levels of high mobility group box 1 protein in patients with bipolar disorder: a pilot study
  publication-title: J. Neuroimmunol.
  doi: 10.1016/j.jneuroim.2019.576993
– volume: 44
  start-page: 1236
  issue: 16
  year: 2010
  ident: 10.1016/j.jpsychires.2021.04.019_bib61
  article-title: Increased serum S100B in never-medicated and medicated schizophrenic patients
  publication-title: J. Psychiatr. Res.
  doi: 10.1016/j.jpsychires.2010.04.023
– volume: 43
  start-page: 1190
  issue: 6
  year: 2017
  ident: 10.1016/j.jpsychires.2021.04.019_bib40
  article-title: 30 Years on: how the neurodevelopmental hypothesis of schizophrenia morphed into the developmental risk factor model of psychosis
  publication-title: Schizophr. Bull.
  doi: 10.1093/schbul/sbx121
– volume: 280
  start-page: 41
  issue: 1
  year: 2017
  ident: 10.1016/j.jpsychires.2021.04.019_bib59
  article-title: Alarmins and immunity
  publication-title: Immunol. Rev.
  doi: 10.1111/imr.12577
– volume: 14
  start-page: 43
  issue: 1
  year: 2017
  ident: 10.1016/j.jpsychires.2021.04.019_bib8
  article-title: HMGB1, IL-1α, IL-33 and S100 proteins: dual-function alarmins
  publication-title: Cell. Mol. Immunol.
  doi: 10.1038/cmi.2016.34
– volume: 80
  start-page: 305
  issue: 2–3
  year: 2005
  ident: 10.1016/j.jpsychires.2021.04.019_bib50
  article-title: Increased serum S100B in elderly, chronic schizophrenic patients: negative correlation with deficit symptoms
  publication-title: Schizophr. Res.
  doi: 10.1016/j.schres.2005.04.013
– volume: 113
  start-page: E2705
  issue: 19
  year: 2016
  ident: 10.1016/j.jpsychires.2021.04.019_bib25
  article-title: IL-33 ameliorates Alzheimer's disease-like pathology and cognitive decline
  publication-title: Proc. Natl. Acad. Sci. U.S.A.
  doi: 10.1073/pnas.1604032113
– volume: 18
  start-page: e27
  issue: 4
  year: 2018
  ident: 10.1016/j.jpsychires.2021.04.019_bib45
  article-title: Damage-associated molecular patterns in inflammatory diseases
  publication-title: Immune. Netw.
  doi: 10.4110/in.2018.18.e27
– volume: 45
  start-page: 499
  issue: 3
  year: 2012
  ident: 10.1016/j.jpsychires.2021.04.019_bib23
  article-title: HMGB1 in development and diseases of the central nervous system
  publication-title: Mol. Neurobiol.
  doi: 10.1007/s12035-012-8264-y
– volume: 9
  start-page: 2379
  year: 2018
  ident: 10.1016/j.jpsychires.2021.04.019_bib3
  article-title: Pattern recognition receptors and the host cell death molecular machinery
  publication-title: Front. Immunol.
  doi: 10.3389/fimmu.2018.02379
– volume: 13
  start-page: 24
  issue: 1
  year: 2013
  ident: 10.1016/j.jpsychires.2021.04.019_bib22
  article-title: Functions of S100 proteins
  publication-title: Curr. Mol. Med.
  doi: 10.2174/156652413804486214
– volume: 13
  start-page: 127
  year: 2019
  ident: 10.1016/j.jpsychires.2021.04.019_bib60
  article-title: The role of high mobility group box 1 in ischemic stroke
  publication-title: Front. Cell. Neurosci.
  doi: 10.3389/fncel.2019.00127
– volume: 30
  start-page: 75
  issue: 2
  year: 2019
  ident: 10.1016/j.jpsychires.2021.04.019_bib30
  article-title: [Inflammation and neurodegeneration in patients with early-stageand chronic bipolar disorder]
  publication-title: Türk PsikiyatriDerg.
– volume: 157
  start-page: 41
  year: 2014
  ident: 10.1016/j.jpsychires.2021.04.019_bib7
  article-title: A preliminary report of increased plasma levels of IL-33 in bipolar disorder: further evidence of pro-inflammatory status
  publication-title: J. Affect. Disord.
  doi: 10.1016/j.jad.2013.12.042
– volume: 7
  start-page: 6
  year: 2010
  ident: 10.1016/j.jpsychires.2021.04.019_bib16
  article-title: Serum levels of S100B and NSE proteins in Alzheimer's disease patients
  publication-title: J. Neuroinflammation
  doi: 10.1186/1742-2094-7-6
– volume: 2020
  start-page: 8465083
  year: 2020
  ident: 10.1016/j.jpsychires.2021.04.019_bib13
  article-title: Alarmins HMGB1, IL-33, S100A7, and S100A12 in psoriasis vulgaris
  publication-title: Mediat. Inflamm.
  doi: 10.1155/2020/8465083
– volume: 40
  start-page: 167
  issue: 1
  year: 2019
  ident: 10.1016/j.jpsychires.2021.04.019_bib6
  article-title: High-sensitivity C-reactive protein and high mobility group box-1 levels in Parkinson's disease
  publication-title: Neurol. Sci.
  doi: 10.1007/s10072-018-3611-z
– volume: 8
  start-page: 55
  issue: 1
  year: 2017
  ident: 10.1016/j.jpsychires.2021.04.019_bib2
  article-title: Interleukin-33 plasma levels in patients with relapsing-remitting multiple sclerosis
  publication-title: Biomol. Concepts
  doi: 10.1515/bmc-2016-0026
– volume: 6
  start-page: 121
  issue: 2
  year: 2007
  ident: 10.1016/j.jpsychires.2021.04.019_bib64
  article-title: Reliability of S100B in predicting severity of central nervous system injury
  publication-title: Neurocrit. Care
  doi: 10.1007/s12028-007-0008-x
– volume: 77
  start-page: 201
  year: 2020
  ident: 10.1016/j.jpsychires.2021.04.019_bib35
  article-title: Schizophrenia-an overview
  publication-title: JAMA. Psychiatry.
  doi: 10.1001/jamapsychiatry.2019.3360
– volume: 148
  start-page: 168
  issue: 2
  year: 2019
  ident: 10.1016/j.jpsychires.2021.04.019_bib37
  article-title: The S100B story: from biomarker to active factor in neural injury
  publication-title: J. Neurochem.
  doi: 10.1111/jnc.14574
– volume: 37
  start-page: 1
  issue: 1
  year: 2016
  ident: 10.1016/j.jpsychires.2021.04.019_bib29
  article-title: Epidemiology and risk factors of schizophrenia
  publication-title: Neuroendocrinol. Lett.
– volume: 81
  start-page: 1
  issue: 1
  year: 2007
  ident: 10.1016/j.jpsychires.2021.04.019_bib9
  article-title: DAMPs, PAMPs and alarmins: all we need to know about danger
  publication-title: J. Leukoc. Biol.
  doi: 10.1189/jlb.0306164
– volume: 8
  start-page: 475
  year: 2017
  ident: 10.1016/j.jpsychires.2021.04.019_bib26
  article-title: The ST2/IL-33 Axis in immune cells during inflammatory diseases
  publication-title: Front. Immunol.
  doi: 10.3389/fimmu.2017.00475
– volume: 65
  start-page: 764
  year: 2010
  ident: 10.1016/j.jpsychires.2021.04.019_bib57
  article-title: White blood cell count and C-reactive protein are independent predictors of mortality in the oldest old
  publication-title: J. Gerontol. A Biol. Sci. Med Sci.
  doi: 10.1093/gerona/glq004
– volume: 69
  start-page: 346
  issue: 5
  year: 2015
  ident: 10.1016/j.jpsychires.2021.04.019_bib58
  article-title: Levels of C-reactive protein (CRP) in patients with schizophrenia, unipolar depression and bipolar disorder
  publication-title: Nord. J. Psychiatr.
  doi: 10.3109/08039488.2014.984755
– volume: 9
  start-page: 271
  year: 2018
  ident: 10.1016/j.jpsychires.2021.04.019_bib12
  article-title: IL-33/ST2 pathway and galectin-3 as a new analytes in pathogenesis and cardiometabolic risk evaluation in psychosis
  publication-title: Front. Psychiatr.
  doi: 10.3389/fpsyt.2018.00271
– volume: 47
  start-page: 74
  year: 2019
  ident: 10.1016/j.jpsychires.2021.04.019_bib33
  article-title: Dual faced HMGB1 plays multiple roles in cardiomyocyte senescence and cardiac inflammatory injury
  publication-title: Cytokine Growth Factor Rev.
  doi: 10.1016/j.cytogfr.2019.05.009
– volume: 120
  start-page: 644
  issue: 5
  year: 2012
  ident: 10.1016/j.jpsychires.2021.04.019_bib36
  article-title: The S100B protein in biological fluids: more than a lifelong biomarker of brain distress
  publication-title: J. Neurochem.
  doi: 10.1111/j.1471-4159.2011.07612.x
– volume: 94
  start-page: 152118
  year: 2019
  ident: 10.1016/j.jpsychires.2021.04.019_bib62
  article-title: Serum high-sensitivity C-reactive protein levels are positively associated with cognitive impairments in patients with first-episode schizophrenia
  publication-title: Compr. Psychiatr.
  doi: 10.1016/j.comppsych.2019.152118
– volume: 95
  start-page: 3818
  issue: 47
  year: 2015
  ident: 10.1016/j.jpsychires.2021.04.019_bib63
  article-title: [Analysis of the changes of serum high mobility group protein B1 and cytokines in first-episode schizophrenia patients]
  publication-title: Zhonghua Yixue Zazhi
– volume: 6
  start-page: 27584
  year: 2016
  ident: 10.1016/j.jpsychires.2021.04.019_bib28
  article-title: Higher plasma S100B concentrations in schizophrenia patients, and dependently associated with inflammatory markers
  publication-title: Sci. Rep.
  doi: 10.1038/srep27584
– volume: 91
  start-page: 59
  year: 2016
  ident: 10.1016/j.jpsychires.2021.04.019_bib48
  article-title: In-vivo evidence that high mobility group box 1 exerts deleterious effects in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model and Parkinson's disease which can be attenuated by glycyrrhizin
  publication-title: Neurobiol. Dis.
  doi: 10.1016/j.nbd.2016.02.018
– year: 2010
  ident: 10.1016/j.jpsychires.2021.04.019_bib52
  article-title: S100B protein, A damage-associated molecular pattern protein in the brain and heart, and beyond
  publication-title: Cardiovasc. Psychiatry. Neurol.
  doi: 10.1155/2010/656481
– volume: 159
  start-page: 209
  issue: 2
  year: 2017
  ident: 10.1016/j.jpsychires.2021.04.019_bib53
  article-title: A review of the clinical utility of serum S100B protein levels in the assessment of traumatic brain injury
  publication-title: Acta Neurochir.
  doi: 10.1007/s00701-016-3046-3
– volume: 151
  start-page: 43
  issue: 1–3
  year: 2013
  ident: 10.1016/j.jpsychires.2021.04.019_bib54
  article-title: Antipsychotics' effects on blood levels of cytokines in schizophrenia: a meta-analysis
  publication-title: Schizophr. Res.
  doi: 10.1016/j.schres.2013.10.011
– volume: 74
  start-page: 96
  year: 2017
  ident: 10.1016/j.jpsychires.2021.04.019_bib19
  article-title: Serum levels of interleukin-33 and its soluble form receptor (sST2) are associated with cognitive performance in patients with schizophrenia
  publication-title: Compr. Psychiatr.
  doi: 10.1016/j.comppsych.2017.01.008
– volume: 35
  start-page: 5931
  issue: 46
  year: 2016
  ident: 10.1016/j.jpsychires.2021.04.019_bib27
  article-title: Damage-associated molecular patterns in cancer: a double-edged sword
  publication-title: Oncogene
  doi: 10.1038/onc.2016.104
– volume: 10
  start-page: 892
  year: 2019
  ident: 10.1016/j.jpsychires.2021.04.019_bib39
  article-title: Cytokine alterations in schizophrenia: an updated review
  publication-title: Front. Psychiatr.
  doi: 10.3389/fpsyt.2019.00892
– volume: 146
  start-page: 211
  issue: 3
  year: 2018
  ident: 10.1016/j.jpsychires.2021.04.019_bib4
  article-title: High-mobility group box 1 in Parkinson's disease: from pathogenesis to therapeutic approaches
  publication-title: J. Neurochem.
  doi: 10.1111/jnc.14450
– volume: 167
  start-page: 66
  issue: 1–2
  year: 2009
  ident: 10.1016/j.jpsychires.2021.04.019_bib51
  article-title: Neuron-specific enolase is unaltered whereas S100B is elevated in serum of patients with schizophrenia--original research and meta-analysis
  publication-title: Psychiatr. Res.
  doi: 10.1016/j.psychres.2008.01.002
– volume: 198
  start-page: 1395
  issue: 4
  year: 2017
  ident: 10.1016/j.jpsychires.2021.04.019_bib44
  article-title: Alarmins: feel the stress
  publication-title: J. Immunol.
  doi: 10.4049/jimmunol.1601342
SSID ssj0007214
Score 2.4763703
Snippet There is growing evidence that immune/inflammatory processes are related to the etiology of schizophrenia. Danger-/damage-associated molecular patterns...
SourceID proquest
pubmed
crossref
elsevier
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 380
SubjectTerms Biomarkers
HMGB1
IL-33
S100B
Schizophrenia
sST2
Title Alarmins (IL-33, sST2, HMGB1, and S100B) as potential biomarkers for schizophrenia
URI https://www.clinicalkey.com/#!/content/1-s2.0-S0022395621002454
https://dx.doi.org/10.1016/j.jpsychires.2021.04.019
https://www.ncbi.nlm.nih.gov/pubmed/33957300
https://www.proquest.com/docview/2524362902
Volume 138
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3dS-QwEA-iIPcift25fhHBBw-2Z5qkbYJPq6ir3vpwKvgWmjSFFe0udn31b3emH6vCCQs-9mPaZjqd-U3zmwkh-1onWQxHAqfx141WIlA55Dwps056EQPkx_8dg-u4fycv76P7OXLS1sIgrbLx_bVPr7x1s-ew0ebheDjEGl8IbQDveVjNH2JPUCkTtPI_r-80D8hw5LRjOJzdsHlqjtdDTSmGxBYyRR5WTU-x587_Q9RXELQKRWfLZKnBkLRXP-YKmfPFKlkcNLPka-RfD9LVp2FR0oOLv4EQXVre3PIu7Q_Oj8MuTYuM3sBojn_TtKTj0QQJQ3A9rMRHss5zSQHJ0vIjHW-d3J2d3p70g2bthMBJFU6CPEq5d4AGtOdJLlkqsgR8rFJZmABkiMM441apFFPUyLFcYYmqyJnOlYsz58VPMl-MCr9BqMstfKmWSw_h3vLISiEgH7cpy2MrEt0hSasu45rG4ri-xaNpGWQP5l3RBhVtmDSg6A4Jp5LjurnGDDK6fSOmLR4Fd2cgAswgezSV_WRkM0rvtQZg4BvEiZW08KMXOCniEoCAZrxDftWWMR2PwIlQwdjmt-69RX7gVs1R2ybzk-cXvwNoaGJ3K3PfJQu9i6v-9RspYQdF
linkProvider Elsevier
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3fb9MwED6NTgJeED9HgQ0j8QBSozm2k9jiqZs2Utb2gXXS3qzYcaROkFZL9_9zbpwA0pAq8Rrnkvhi331nf3cG-KhUVqbYElnll26U5JGsMOYpqLHC8RQhv1_vmM3T_Ep8u06u9-C0y4XxtMpg-1ubvrXW4cpx0Obxern0Ob7o2hDes3i7fygewL6vTpUMYH88ucjnvUHGIEf0RcNRIBB6WprXTcsqxtgWg0UWb-ue-rI793upf6HQrTc6fwpPAowk4_ZLn8Geq5_Dw1nYKH8B38cYsf5c1g35NJlGnI9Ic7lgI5LPvp7EI1LUJbnEDp18JkVD1quN5wzh83wyvufr3DYEwSxp_mTkvYSr87PFaR6F4xMiK2S8iaqkYM4iIFCOZZWgBS8zNLNSlnGGqCGN05IZKQsfpSaWVtJnqfKKqkratLSOv4JBvardayC2MjhZDRMOPb5hiRGcY0huClqlhmdqCFmnLm1DbXF_xMUP3ZHIbvRvRWuvaE2FRkUPIe4l1219jR1kVPdHdJc_ihZPoxPYQfZLL_vXONtR-kM3ADROQ7-3UtRudYc3JUwgFlCUDeGgHRl9f7jfC-WUvvmvd7-HR_liNtXTyfziLTz2LS1l7R0MNrd37hDB0cYchcH_CypJCfY
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Alarmins+%28IL-33%2C+sST2%2C+HMGB1%2C+and+S100B%29+as+potential+biomarkers+for+schizophrenia&rft.jtitle=Journal+of+psychiatric+research&rft.au=Koz%C5%82owska%2C+El%C5%BCbieta&rft.au=Brzezi%C5%84ska-B%C5%82aszczyk%2C+Ewa&rft.au=Agier%2C+Justyna&rft.au=Wysoki%C5%84ski%2C+Adam&rft.date=2021-06-01&rft.eissn=1879-1379&rft.volume=138&rft.spage=380&rft_id=info:doi/10.1016%2Fj.jpsychires.2021.04.019&rft_id=info%3Apmid%2F33957300&rft.externalDocID=33957300
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0022-3956&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0022-3956&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0022-3956&client=summon